Skip to content
DataLookout
Menu

NCT07141329

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

StatusEnrolling by Invitation
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 4 words Show 4 more changesShow less
    • Trial status changed: Recruiting → Enrolling by Invitation
    • Trial sites expanded: 1 → 8 locations
    • Secondary endpoints revised (4)
    • Study description expanded, about 12 words
  2. Notable Phase: Phase 3 to Phase 2
    • Study description shortened, about 6 words
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of treatment-emergent adverse events
Timeframe: Week 1-Week 52

Secondary (4)

Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the 1-year SPN-817 Treatment Period
Proportion of participants experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
Proportion of participants experiencing seizure freedom
Percentage of seizure-free days over the 1-year SPN-817 Treatment Period

Arms and interventions

SPN-817Experimental

SPN-817, bid

Drugs: SPN-817

Sites

8 sites in 2 countries

United States 7, Australia 1